Clopidogrel Is More Effective Than Aspirin at Staving Off Third CVE

Susan Farley
Published Online: Thursday, April 1, 2004

In a study of 4496 patients at a high risk for another heart attack or stroke, researchers found that the anticlotting drug clopidogrel produced a 14.9% lower relative risk for hospitalization or death from a cardiovascular event (CVE). A year after their second CVE, 16.1% of clopidogrel users suffered another heart attack, stroke, or CVE, compared with 18.5% of patients taking aspirin. Three years after their first CVE, statistics showed that 20.4% of patients taking clopidogrel and 23.8% of patients taking aspirin had died from a CVE. Deepak L. Bhatt, MD, study coauthor and director of the Interventional Cardiology Fellowship at the Cleveland Clinic Foundation in Ohio, concluded, "Basically, if a patient has a history of multiple cardiovascular events, [he or she is] better off being treated with clopidogrel rather than aspirin."

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues